These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17164114)

  • 1. The economics of hepatitis C virus.
    Shah BB; Wong JB
    Clin Liver Dis; 2006 Nov; 10(4):717-34. PubMed ID: 17164114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there discrimination in access to therapy for HCV patients?
    Garattini S
    J Hepatol; 2008 Oct; 49(4):491-3. PubMed ID: 18678432
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?
    Wedemeyer H
    Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):76-8. PubMed ID: 23296251
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost effectiveness evaluation of hepatitis C therapy in Lahore.
    David YJ; Tahir A; Riaz M
    Pak J Pharm Sci; 2017 Nov; 30(6):2233-2237. PubMed ID: 29175794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders.
    Nakamura J; Toyabe SI; Aoyagi Y; Akazawa K
    J Viral Hepat; 2008 Apr; 15(4):293-9. PubMed ID: 18307591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.
    Gerkens S; Nechelput M; Annemans L; Peraux B; Mouchart M; Beguin C; Horsmans Y
    J Viral Hepat; 2007 Aug; 14(8):523-36. PubMed ID: 17650286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Because fee settlement means are not widely known. Deficits in hepatitis C therapy].
    MMW Fortschr Med; 2003 May; 145(19):55. PubMed ID: 12813986
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacoeconomic analysis of treatment of patients infected with hepatitis C virus.
    Qureshi S; Qazi MH; Aziz MT
    Pak J Pharm Sci; 2018 Mar; 31(2):365-369. PubMed ID: 29618422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy for hepatitis C infection.
    Newman TB
    N Engl J Med; 1999 Apr; 340(15):1207; author reply 1208-9. PubMed ID: 10206843
    [No Abstract]   [Full Text] [Related]  

  • 11. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.
    Annemans L; Warie H; Nechelput M; Peraux B
    Acta Gastroenterol Belg; 2004; 67(1):1-8. PubMed ID: 15149079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
    Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
    Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.
    Wisløff T; White R; Dalgard O; Amundsen EJ; Meijerink H; Løvlie AL; Kløvstad H
    Pharmacoeconomics; 2018 May; 36(5):591-601. PubMed ID: 29396744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden associated with patients diagnosed with hepatitis C.
    McCombs JS; Yuan Y; Shin J; Saab S
    Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
    Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
    Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UNITAID can address HCV/HIV co-infection.
    von Schoen-Angerer T; Cohn J; Swan T; Piot P
    Lancet; 2013 Feb; 381(9867):628. PubMed ID: 23439101
    [No Abstract]   [Full Text] [Related]  

  • 17. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
    Hornberger J; Farci P; Prati D; Zeuzem S; Green J; Patel KK
    J Viral Hepat; 2006 Jun; 13(6):377-86. PubMed ID: 16842440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.
    Smith JA; Kalimullah FA; Erickson CP; Peng LS
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacoeconomic appraisal of therapies for hepatitis B and C.
    Younossi ZM; Temple ME; Shermock KM
    Expert Opin Pharmacother; 2001 Feb; 2(2):205-11. PubMed ID: 11336580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.